SynOx Therapeutics will present primary results from the Phase 3 TANGENT trial of emactuzumab in tenosynovial giant cell tumor (TGCT) at the ESMO Congress 2026 in Madrid, Spain. The data, accepted as a Late-Breaking Abstract (LBA89), will be shared in a Proffered Paper Oral Presentation during the Sarcoma session on Saturday, October 24, 2026, from 14:45 to 16:15 CEST in the Malaga Auditorium – Hall 3. Emactuzumab is an investigational agent and has not been approved by any regulatory authority.
ESMO Congress
23-27 October in Madrid
